Context Therapeutics Inc. (CNTX) Stock Forecast
CNTX analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 10 analysts
- Price target
- $4.03 average of analyst targets
- Upside to target
- +1,552.7% from the latest close
- Next earnings
- November 4, 2026 EPS estimate $-0.09
- 52-week range
- $0.24 – $3.36
CNTX analyst ratings
10 analystsNumber of analysts at each rating.
CNTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CNTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.11 | −$0.16 | −$0.07 | −$0.10 | −7.5% | 8 |
| Current fiscal year (2026) | −$0.46 | −$0.57 | −$0.40 | −$0.38 | −21.1% | 8 |
| Next fiscal year (2027) | −$0.44 | −$0.59 | −$0.37 | −$0.46 | +5.3% | 7 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CNTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | 0.0% | 8 |
| Current fiscal year (2026) | $0 | $0 | $0 | 0.0% | 8 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 8 |
CNTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CNTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.10 | −$0.10 | −$0.10 | −$0.10 | −$0.11 | +11.6% | 2 up · 3 down |
| Current fiscal year (2026) | −$0.39 | −$0.39 | −$0.39 | −$0.45 | −$0.46 | +17.9% | 1 up · 6 down |
| Next fiscal year (2027) | −$0.43 | −$0.43 | −$0.43 | −$0.41 | −$0.44 | +1.0% | 4 up · 2 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CNTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CNTX beat in 5 of 12.
What analysts expect from CNTX
10 analysts cover Context Therapeutics; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $4.03, 1,552.7% above the latest close of $0.24. Analysts expect earnings of −$0.46 per share for 2026, −21.1% from a year earlier. For 2027 the average estimate is −$0.44 per share. Context Therapeutics beat the EPS estimate in 5 of the last 12 quarters.
Related: CNTX income statement, CNTX key metrics, CNTX chart. See the CNTX stock overview for the latest quote and news.
CNTX forecast FAQ
What is Context Therapeutics's price target?
The average analyst price target for Context Therapeutics is $4.03, 1,552.7% above the latest close of $0.24.
Is Context Therapeutics a buy, hold or sell?
Of 10 analysts covering Context Therapeutics, 6 rate it a strong buy, 3 a buy, 1 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Context Therapeutics's EPS forecast?
Analysts forecast −$0.46 per share for 2026 (range −$0.57 to −$0.40); for 2027 the estimate is −$0.44.
When does Context Therapeutics report earnings?
Context Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 4, 2026; the EPS estimate is $-0.09.
Does Context Therapeutics usually beat earnings estimates?
Context Therapeutics reported EPS at or above the analyst estimate in 5 of the last 12 quarters.